PSP Research’s Beam Therapeutics BEAM Stock Holding History

PSP Research’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,334	Closed	-$508K	–	83
2025 Q4	$508K	Buy	+18,334	New	+$468K	0.44%	71

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

PSP Research's BEAM Position: Q1 2026 in Review

PSP Research sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 18,334 shares — an estimated $508K sold.

PSP Research first reported a position in BEAM in Q4 2025 and held it in 1 quarter. The position peaked at $508K in Q4 2025. 253 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

PSP Research reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
PSP Research sold 18,334 Beam Therapeutics shares in Q1 2026, an estimated $508K.
PSP Research first reported a position in Beam Therapeutics in Q4 2025 and held it in 1 quarter.
PSP Research's Beam Therapeutics position peaked at $508K in Q4 2025.
253 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.